Access Update: BMS Offers Deep Discounts on Deucravacitinib (Sotyktu)
Bristol Myers Squibb (BMS) is expanding its direct-to-patient offerings, providing eligible U.S. patients with steeply discounted prices for deucravacitinib (Sotyktu) and apixaban A (Eliquis). Eligible cash-pay patients can now purchase these medicines directly from BMS and significantly lower their out-of-pocket costs. Beginning January 2026, deucravacitinib will be offered through the new BMS Patient Connect platform, […]